AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Hodgkin Lymphoma
  • Age: Between 5 Year(s) - 60 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients who have recently been diagnosed with a specific type of Hodgkin lymphoma called classic Hodgkin lymphoma (cHL) and have not received any treatment for their condition yet
    2. Patients must have measurable disease which includes at least one lesion with longest diameter greater than or equal to 1.5 cm
    3. Patients must have a whole body or limited whole body PET scan performed within 42 days prior to enrollment

You may not be eligible for this study if the following are true:

    1. Nodular lymphocyte predominant Hodgkin Lymphoma
    2. A history of active interstitial pneumonitis or interstitial lung disease
    3. A diagnosis of inherited or acquired immunodeficiency that is poorly controlled or requiring active medications



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.